title: [New antivirals against hepatitis C virus].
abstract: Recently, first direct acting antiviral (DAA) against hepatitis C virus (HCV) has just approved in Japan. It is a first generation protease inhibitor, telaprevir. Telaprevir inhibits HCV NS3 & 4A serine protease, and combination with pegylated-interferon and ribavirin has now become a standard of care (SOC) for patients with genotype 1 high viral load hepatitis C. Fortunately, more than 50 new antivirals against HCV are under development including antivirals in preclinical trials. New antivirals are classified into several categories; (1) NS3 & 4A protease inhibitor, (2) NS5B polymerase inhibitor, (3) NS5A inhibitor, (4) host factor targeting antivirals, (5) interferon-related antivirals, and others. Combination of different classes of antivirals without interferon is expected to become a future SOC for hepatitis C.
authors.affiliation: Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo.
authors.forename: Naoya
authors.initials: N
authors.lastname: Kato
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Muroyama
authors.forename: Kaku
authors.initials: K
authors.lastname: Goto
mesh_terms: D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D004792:Enzyme Precursors / Q000037:antagonists & inhibitors; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors
chemical_list: D004792:Enzyme Precursors; D012321:DNA-Directed RNA Polymerases; C022443:proelastase; D010196:Pancreatic Elastase